Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mitsubishi Tanabe Pharma Corporation

http://www.mt-pharma.co.jp/e/index.php

Latest From Mitsubishi Tanabe Pharma Corporation

Japan’s CEA Scheme: How It Works And Impact So Far

Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?

Japan Health Technology Assessment

Finance Watch: CARGO Gets A Lukewarm Reception After Stock Market Debut

Public Company Edition: CARGO Therapeutics grossed $281.3m, giving it the fifth-largest biopharma IPO this year. Also, Alkermes completed its cancer business spinout as Mural Oncology, which launched with $275m, and Xencor sold Ultomiris and Monjuvi royalties for $215m.

Financing Growth

Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds

Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.

Financing Innovation

Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023

Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.

Financing Growth
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Nutraceuticals
    • OTC, Consumer
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • BIXEN Corporation
    • Medicago Inc.
    • Mitsubishi Tanabe Pharma America, Inc. (MTPA)
    • Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA)
    • Mitsubishi Tanabe Pharma Singapore Pte. Ltd.
    • NeuroDerm, Ltd. (NDRM)
    • PT Mitsubishi Tanabe Pharma Indonesia
    • Mitsubishi Tanabe Pharma (Thailand)
    • MT Pharma Singapore PTE. Ltd.
    • Tai Tien Pharmaceuticals Co., Ltd.
    • Tanabe Research Laboratories U.S.A.
UsernamePublicRestriction

Register